Men with lower total testosterone or dihydrotestosterone face elevated cancer mortality risk, while mid-range sex hormone-binding globulin (SHBG) and luteinizing hormone concentrations correlate with reduced cancer death risk. These hormonal patterns function as measurable indicators of cancer vulnerability, suggesting testosterone and related hormones warrant evaluation as clinical biomarkers for cancer risk stratification.
Key Points
- Lower testosterone associated with higher cancer death risk in men
- Mid-range SHBG and LH protect against cancer mortality
- Low SHBG and LH increase incident prostate cancer risk
Longevity Analysis
Testosterone and its metabolic byproducts operate as more than reproductive hormones—they signal systemic health status relevant to cancer risk. The protective effect of mid-range SHBG suggests that hormonal balance, not simply elevated levels, matters for survival outcomes. Men who can accurately measure and interpret these hormone concentrations gain a quantifiable pathway to identify cancer vulnerability before clinical disease emerges, enabling targeted prevention strategies rather than waiting for symptoms. This positions hormonal profiling as a foundational assessment tool, particularly for men at midlife when cancer incidence begins its steep rise.
Original published by The Lancet Healthy Longevity, by Ross J Marriott, Kevin Murray, Leen Antonio, Robert J Adams, Christie M Ballantyne, Douglas C Bauer, Shalender Bhasin, Mary L Biggs, Peggy M Cawthon, David J Couper, Adrian S Dobs, Leon Flicker, Nele Friedrich, David J Handelsman, Graeme J Hankey, Anke Hannemann, Calvin H Hirsch, Benjumin Hsu, Sean A Martin, Alvin M Matsumoto, Claes Ohlsson, Terence W O'Neill, Eric S Orwoll, Thomas G Travison, Dirk Vanderschueren, Robin Wilkening, Gary A Wittert, Frederick C W Wu, Bu B Yeap.